China
Africa
Explore chapters and articles related to this topic
Monographs of Topical Drugs that Have Caused Contact Allergy/Allergic Contact Dermatitis
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
Latanoprost is a prostaglandin F2α analog and a prostanoid selective FP receptor agonist with an ocular antihypertensive effect. It increases outflow of aqueous fluid from the eyes and thereby reduces intraocular pressure. Latanoprost is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension (1).
Pea
Published in Sahar Swidan, Matthew Bennett, Advanced Therapeutics in Pain Medicine, 2020
Costagliola et al.26 performed an open-label 6-month study on the effects of PEA on visual field damage progression in patients with normal tension glaucoma (NTG). This is a form of glaucoma that is characterized by optic nerve damage and vision loss despite normal intraocular pressure levels. Thirty-two patients were split equally between a treatment group with PEA and a control group that received no treatment. All of the patients who participated in the study had been treated with once-daily latanoprost for at least 3 months. The participants in the treatment group were instructed to take one tablet after breakfast and dinner for 6 months. Best corrected visual acuity (BCVA), intraocular pressure (IOP) with the patient in a sitting position, central corneal thickness, and blood pressure were measured at baseline. The researchers reported that IOP dropped from a mean value of 14.4 to 11.1 in patients treated with PEA. There were no statistically significant changes in the BCVA. The mean deviation and pattern standard deviation visual field parameters diminished in the PEA group compared to the control. The findings of this study show that PEA can be helpful in reducing IOP and recovering mean deviation and pattern standard deviation in glaucoma patients suffering from normal tension glaucoma.
Communicating Information
Published in Vilius Savickas, Reem Kayyali, Neel Sharma, Student Success in the Prescribing Safety Assessment (PSA), 2020
Vilius Savickas, Reem Kayyali, Neel Sharma
Mr Ahmed has recently been prescribed latanoprost eye drops 0.005% by the hospital ophthalmologist. He has found it hard to understand the patient information leaflet; therefore, he would like you to provide him with some information about the use of these eye drops and any problems that may arise during the treatment.
Sustained release ocular drug delivery systems for glaucoma therapy
Published in Expert Opinion on Drug Delivery, 2023
Zinah K. Al-Qaysi, Ian G. Beadham, Sianne L. Schwikkard, Joseph C. Bear, Ali A. Al-Kinani, Raid G. Alany
The Evolute/Latanoprost Punctual Plug Delivery System (L-PPDS) (Mati Therapeutics, Austin, TX, U.S.A) was developed for lowering. The L-shaped punctual plug is composed of a core of latanoprost-polymer (cyanoacrylate) matrix surrounded by silicone. The reservoir matrix has an opening through which the drug is released after coming into contact with the tear film [111,112]. Mati Therapeutics has conducted two open-label phase II clinical trials to evaluate the safety and efficacy of various L-PPDS formulations for the treatment of open-angle glaucoma [111]. The first study included two groups treated with two dosages of latanoprost, 44 μg (group 1), and 81 μg (group 2) for 6 weeks. The punctual plug retention rate was high for both groups 77% (group 1) and 94% (group 2), yet loss of the plug or inadequate IOP control were the main reasons for discontinuation of treatment. The most common adverse effects reported were foreign body sensation and itching. Conjunctival hyperemia was also reported, but this was exclusively in group 2 [113]. In the second clinical study, participants were treated with two different formulations of 95 μg latanoprost for 12 weeks. The results showed a 20% reduction in IOP at three months with 92% plug retention. The punctual plugs had lowered the ocular pressure by 7 mm Hg compared with a 5 mm Hg reduction using latanoprost eye drops [53,113].
Sustained latanoprost release from PEGylated solid lipid nanoparticle-laden soft contact lens to treat glaucoma
Published in Pharmaceutical Development and Technology, 2022
Hui Dang, Chunyun Dong, Li Zhang
Latanoprost is an ester analogue that reduces the intra ocular pressure (IOP) by increasing the uveoscleral outflow (Watson et al. 1996). It is widely accepted for the treatment of ocular hypertension using eye drop solution (Rouland et al. 2013). However, eye drop therapy shows poor ocular bioavailability due to loss of drug via nasolacrimal drainage, improper absorption, and other associated corneal barriers (Desai et al. 2019; Lanier et al. 2021; Maulvi et al. 2021). The poor patient compliance and low adherence rate (<50%) contribute to irreversible vision loss (Schwartz and Quigley 2008; Friedman et al. 2009). The patient adherence to glaucoma therapy can be improved by developing therapeutic contact lenses to deliver drugs for the prolong period of time (Gupta and Aqil 2012; Holgado et al. 2020). The contact lens can improve ocular bioavailability up to 50% compared to eye drop solutions (Hiratani et al. 2005; Maulvi et al. 2021). Formulators have developed methods to incorporate ophthalmic drugs into the contact lenses, including molecular imprinting, use of vitamin E as a barrier, polymeric nanoparticles, application of supercritical fluids, implantation techniques, and coating (Guzman-Aranguez et al. 2013; Maulvi et al. 2016). Although these approaches afforded controlled and prolonged drug release profiles with improved ocular drug retention, they are not suitable for clinical application owing to alterations in the critical properties of the lens, such as swelling, oxygen permeability, and optical transparency (Lanier et al. 2020; Zhang et al. 2020).
Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma
Published in Drug Development and Industrial Pharmacy, 2020
Dina Fathalla, Ehab A. Fouad, Ghareb M. Soliman
Latanoprost is an esterified prodrug of prostaglandin F2α, which effectively lowers IOP through enhancing uveoscleral outflow [7]. Its hydrophobicity promotes good absorption through the cornea followed by hydrolysis to its active form latanoprost acid [8,9]. Latanoprost is commercially available as eye drops, which suffer from rapid drug loss from the eye and diurnal IOP fluctuation [10]. Further, only a limited fraction of the administered dose (∼5%) is absorbed through the cornea [11]. Given these limitations, there is a strong need to develop sustained release delivery systems for latanoprost to reduce its frequency of administration and enhance its efficacy. To this end, we have recently shown that latanoprost liposomal gel was able to sustain latanoprost release and prolong its anti-glaucoma effect in rabbits [12]. Other research groups showed that subconjunctival injection of liposomal latanoprost could prolong its release for up to 120 days [10,11,13]. However, low chemical stability of liposomes and the invasive nature of subconjunctival injection make it important to develop alternative delivery systems.